These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29271103)

  • 21. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.
    Khurana M; Vaidyanathan J; Marathe A; Mehrotra N; Sahajwalla CG; Zineh I; Jain L
    J Clin Pharmacol; 2015 Jun; 55(6):647-56. PubMed ID: 25612234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
    Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
    Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal effects of canagliflozin in type 2 diabetes mellitus.
    Perkovic V; Jardine M; Vijapurkar U; Meininger G
    Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
    Davies MJ; Trujillo A; Vijapurkar U; Damaraju CV; Meininger G
    Diabetes Obes Metab; 2015 Apr; 17(4):426-9. PubMed ID: 25600248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.
    Devineni D; Murphy J; Wang SS; Stieltjes H; Rothenberg P; Scheers E; Mamidi RN
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):295-304. PubMed ID: 27136910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
    Inagaki N; Kondo K; Yoshinari T; Ishii M; Sakai M; Kuki H; Furihata K
    Clin Drug Investig; 2014 Oct; 34(10):731-42. PubMed ID: 25200141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS.
    Dong ST; Niu HM; Wu Y; Jiang JL; Li Y; Jiang KY; Wang X; Zhang MF; Han MF; Meng SN
    Molecules; 2018 May; 23(5):. PubMed ID: 29783787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
    Adachi J; Inaba Y; Maki C
    Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
    Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.
    Shao YL; Yee KH; Koh SK; Wong YF; Yeoh LY; Low S; Sum CF
    Singapore Med J; 2018 May; 59(5):251-256. PubMed ID: 29022040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.